ARA 290: The “Innate Repair” Signal for Advanced Neuropathy Research

04/02/2026 | Bio Bulk Peptides |

Molecular Specifications

  • Molecular Formula: C₅₁H₈₄N₁₆O₂₁
  • Molecular Weight: 1257.3 g/mol
  • Sequence: pyroGlu-Glu-Gln-Glu-Arg-Ala-Val-Ala-Glu-Arg-Ala (11-amino acid peptide)
  • CAS Number: 1208240-58-1
  • Other Names: Cibinetide, ARA 290
  • Structure: Derived from the B-helix of the Erythropoietin (EPO) molecule
  • Application: For Research Use Only (FRUO)

Investigating the Origins of ARA 290

ARA 290 is a synthetic 11-amino acid peptide specifically engineered to mimic the tissue-protective properties of erythropoietin (EPO) without inducing the hematopoietic (red blood cell production) effects associated with the full-length hormone. In biological systems, EPO is recognized primarily for its role in stimulating erythropoiesis through the homodimeric Erythropoietin Receptor (EPOR₂). However, research conducted over the last two decades has identified a secondary, alternative signaling pathway utilized by EPO during times of cellular stress or injury.

This alternative pathway involves a heteromeric receptor complex known as the Innate Repair Receptor (IRR). While full-length EPO binds to both the erythropoietic homodimer and the tissue-protective heteromer, it carries the risk of inducing excessive red blood cell production, which can lead to hypertension and thrombosis in non-anemic subjects. ARA 290 was developed to selectively target the IRR, providing a molecular tool to explore tissue repair and neuroprotection without altering hematological parameters.

The peptide is derived specifically from the B-helix of the EPO protein. By isolating this specific sequence, researchers have produced a ligand that maintains a high affinity for the IRR while remaining inert toward the EPOR₂ homodimer. This selectivity makes it a primary candidate for studying chronic inflammatory conditions and neuropathic damage.

Molecular structure of ARA 290 peptide targeting the Innate Repair Receptor.

The Mechanism of the Innate Repair Receptor (IRR)

The Innate Repair Receptor (IRR) is a heterocomplex consisting of the erythropoietin receptor (EPOR) and the CD131 (common beta chain). Unlike the standard erythropoietin receptor found on erythroid progenitor cells, the IRR is typically not expressed under homeostatic conditions. Instead, it is upregulated on the surface of various cell types, including neurons, macrophages, and endothelial cells, only following injury, metabolic stress, or exposure to pro-inflammatory cytokines.

Selective Signaling Pathways

When ARA 290 binds to the IRR, it initiates a distinct intracellular signaling cascade. This process typically involves:

  1. JAK2 Activation: The Janus kinase 2 pathway is triggered, which is a common feature in cytokine receptor signaling.
  2. STAT Modulation: Signal transducer and activator of transcription proteins are influenced, leading to the transcription of cytoprotective genes.
  3. PI3K/Akt Pathway: Activation of the phosphoinositide 3-kinase pathway has been observed, which may play a role in promoting cell survival and inhibiting apoptosis (programmed cell death).

By focusing exclusively on the IRR, ARA 290 research explores how to decouple the biological "repair" signal from the "production" signal of EPO. This distinction is critical in laboratory environments focusing on long-term chronic disease models where the side effects of standard EPO would be prohibitive.

Neuroprotection and Nerve Regeneration Research

One of the most prominent areas of interest for ARA 290 is its potential role in managing neuropathic damage. Neuropathy, particularly Small Fiber Neuropathy (SFN), involves the selective damage of small, unmyelinated C-fibers and thinly myelinated A-delta fibers. These fibers are responsible for transmitting thermal and nociceptive (pain) information, as well as maintaining autonomic functions.

Small Fiber Neuropathy (SFN) and Sarcoidosis

In research models involving sarcoidosis, a systemic inflammatory disease, the prevalence of SFN is high. Studies have utilized ARA 290 to investigate whether activating the IRR can reverse the loss of small nerve fibers. A key metric in these studies is the measurement of Corneal Nerve Fiber Density (CNFD). Because the cornea is highly innervated by small fibers, non-invasive imaging allows researchers to track structural nerve changes in real-time. Preclinical and early-phase data suggest that IRR activation may support the regrowth of these fibers, potentially modifying the underlying pathology rather than merely masking symptoms.

Diabetic Neuropathy Models

Research into Type 2 Diabetes often utilizes ARA 290 to explore the impact of metabolic stress on peripheral nerves. Hyperglycemia induces oxidative stress and local inflammation, which degrades small nerve fibers over time. Investigating the administration of ARA 290 in these models has shown a correlation with increased nerve fiber branching and improved sensory thresholds, suggesting a structural regenerative effect.

Illustration of small fiber nerve regeneration and increased fiber density.

Anti-Inflammatory Mechanisms and the NLRP3 Inflammasome

The tissue-protective effects of ARA 290 are intrinsically linked to its ability to modulate the immune response. In many chronic conditions, the persistence of a "pro-inflammatory" state prevents successful tissue repair. ARA 290 has been studied for its ability to shift macrophages from a pro-inflammatory (M1) phenotype to an anti-inflammatory/repair (M2) phenotype.

Suppression of Pro-Inflammatory Cytokines

In cellular assays, ARA 290 has demonstrated the capacity to suppress the production of:

  • TNF-alpha (Tumor Necrosis Factor-alpha): A primary driver of systemic inflammation.
  • IL-6 (Interleukin-6): A cytokine associated with chronic inflammatory states and autoimmune responses.

The NLRP3 Inflammasome

Recent research has highlighted the role of the NLRP3 inflammasome in neuropathy and metabolic disease. The NLRP3 complex is an intracellular sensor that triggers the release of pro-inflammatory cytokines like IL-1β in response to cellular damage. ARA 290 is investigated for its potential to antagonize NLRP3 activation. By inhibiting this inflammasome, the peptide may prevent the downstream "cytokine storm" that leads to irreversible nerve damage.

Bridging Immune Modulation and Nociception: TRPV1 Antagonism

A novel and highly significant angle in ARA 290 research is its potential interaction with the TRPV1 (Transient Receptor Potential Vanilloid 1) channel. TRPV1 is a non-selective cation channel found on peripheral sensory neurons. It is famously known as the "heat" or "capsaicin" receptor and plays a central role in thermal hyperalgesia (increased sensitivity to pain).

Current research suggests that ARA 290 may act as a TRPV1 channel antagonist. This is significant because it provides a dual mechanism of action:

  1. Immune Modulation: Reducing the inflammatory environment that sensitizes nerves.
  2. Direct Nociception Inhibition: Potentially blocking the actual transmission of pain signals at the receptor level.

This dual-pronged approach is a major focal point for studies involving chronic neuropathic pain conditions, where central sensitization often makes standard treatments ineffective.

Visualization of ARA 290 protecting cellular structures from inflammatory cytokines.

Comparative Analysis: ARA 290 vs. Erythropoietin (EPO)

Feature Erythropoietin (EPO) ARA 290 (Cibinetide)
Primary Target EPOR₂ Homodimer & IRR IRR (EPOR/CD131 Heteromer)
Erythropoietic Activity High (Increases RBC count) None (No effect on RBCs)
Tissue Protection High High
Thrombotic Risk Present in non-anemic subjects Negligible in research models
Half-Life Several hours Short (~2-5 minutes in plasma)
Molecular Size 30.4 kDa (Protein) 1.25 kDa (Peptide)

Despite its short half-life in systemic circulation, the effects of ARA 290 appear to be long-lasting. This is likely due to the "hit-and-run" nature of IRR activation, where a brief binding event triggers a prolonged intracellular signaling cascade that persists well after the peptide has been cleared from the bloodstream.

Research Applications and Future Directions

Research institutions utilizing ARA 290 often focus on long-term longitudinal studies to observe the structural repair of neural tissue. Areas of ongoing investigation include:

  • Autoimmune Research: Exploring its effects in models of Lupus and Sarcoidosis.
  • Cardiovascular Protection: Investigating the impact on ischemia-reperfusion injury.
  • Neurodegenerative Disease: Studying the peptide's ability to cross the blood-brain barrier (BBB) or influence neuroinflammation from the periphery.

For laboratories conducting high-volume or long-duration studies, sourcing high-purity material is essential. BioBulkPeptides provides high-purity ARA 290 in bulk quantities, ensuring consistency across large-scale research cohorts and long-term experimental protocols. Researchers can view Certificates of Analysis (COAs) to verify the purity and identity of the material before beginning their studies.

High-purity ARA 290 peptide vial in a professional laboratory research setting.

Storage and Handling Instructions

To maintain the structural integrity and biological activity of ARA 290, stringent storage protocols must be followed:

  • Lyophilized Powder: Store at -20°C for long-term stability. For short-term use (less than 4 weeks), storage at 2-8°C is acceptable.
  • Reconstituted Solution: Once reconstituted with bacteriostatic water or sterile saline, the peptide should be kept at 2-8°C and used within a short timeframe to prevent degradation.
  • Light Sensitivity: Keep the vial protected from direct light exposure.

Summary of Research Potential

ARA 290 represents a significant shift in how neuroprotection and tissue repair are studied. By selectively engaging the Innate Repair Receptor, it allows for the exploration of regenerative pathways without the confounding variables of altered blood viscosity or increased hematocrit levels. Whether investigating nerve regeneration, NLRP3 inhibition, or TRPV1 antagonism, this peptide remains a cornerstone of modern neuro-immunology research.

For more information on available research compounds, visit the BioBulkPeptides products page.

DISCLAIMER: All products listed on biobulkpeptides.com, including ARA 290, are intended strictly for laboratory research purposes only. These compounds are not intended for human or veterinary use. They are not for use in food, drugs, medical devices, or cosmetics. Any mention of biological effects or research findings refers exclusively to preclinical studies conducted in laboratory settings.

For Research Use Only. Not for human consumption.

Bulk orders for institutional research are processed with priority shipping. Please consult our Terms of Service for compliance details regarding research materials.